The 64th Annual Meeting of ASH came to an end on December 14, 2022, Beijing time. At this meeting, Precision Biotech disclosed the latest clinical progress of its self-developed CAR-T and universal CAR-T product candidate.

The C-13-60 cell preparation, a candidate product of Chongqing Precision Biotech, is a CEA CAR-T cell injection for the treatment of patients with CEA-positive advanced malignant solid tumors aged ≥18 years. Its clinical trial application has been submitted in September 2022. On March 22, it was accepted by NMPA.

The 2022 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from June 3 to June 7. This world's top clinical oncology conference includes Clinical Science Symposiu...

The 2022 American Society of Clinical Oncology Annual Meeting (ASCO) will be held in Chicago, USA from June 3 to June 7, 2022 EST. The conference includes Clinical Science Symposium, Oral Abstract Session, Poster Discussion Session (poster discussion) and other links, and a total of 35 domestic related research reports. Among them, there are 6 reports related to the field of CAR cell therapy. Chongqing Precision Biotech Co., Ltd. will publish the clinical results of the product MC-1-50 based on the PrimeCARTM platform.